Asia Pacific TB Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Nucleic Acid Testing (NAT), Skin Test / Mantoux Test (TST), Blood Test / Serology Test, SMEAR Microscopy, Cultured-Based Tests, Radiography Tests, Others), By End-User (Hospitals and Diagnostic Laboratories, Physician’s Office Laboratories, Reference Laboratories, Academics and Research Facilities) and By Country (China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2026-2034

Asia Pacific TB Diagnostics Market Size & Growth Analysis

The Asia Pacific TB diagnostics market size was valued at USD 340.00 million in 2025 and is projected to grow from USD 364.21 million in 2026 to USD 631.41 billion by 2034, exhibiting a CAGR of 7.12% during the forecast period 2026–2034.

The bacteria Mycobacterium tuberculosis causes tuberculosis, which is an infectious illness (MTB). Tuberculosis usually affects the lungs, but it may also affect other regions of the body. Most TB infections are asymptomatic, known as latent tuberculosis. If left untreated, around 10% of latent infections progress to active disease, killing half of the affected people.

Active TB symptoms include a chronic cough with bloody mucus, fever, night sweats, and weight loss. The most frequent TB diagnostic procedure is a skin test; however, blood tests are becoming more widespread. During the projected period, the Asia Pacific TB diagnostics and treatment market is expected to develop at a CAGR of roughly 2.8%. Asia had the highest number of new TB cases, accounting for 45% of all new cases. Tuberculosis incidence and mortality rates were shown to be greater in nations with poorer human development indexes, GDP per capita, corruption perception indexes, and populations receiving minimal food supplements. Among the health-system factors, governmental health spending per capita, total health spending per capita, increased water availability, hospital beds, and sanitation are all substantially linked to TB. Because Asia is home to most poor nations, the absence of these system characteristics raises TB rates across the Asia-Pacific area.

Asia Pacific TB Diagnostics Market Segmentation Analysis

By Test Type

Nucleic Acid Testing (NAT) supports rapid TB detection by identifying genetic material associated with Mycobacterium tuberculosis, making it useful when timely diagnosis is important. Skin Test / Mantoux Test (TST) is used to assess an immune response associated with TB infection and remains relevant for screening and clinical evaluation. Blood Test / Serology Test provides an additional diagnostic approach for assessing immune or biological responses related to TB, depending on the specific testing method. SMEAR Microscopy remains useful because it is a comparatively simple laboratory technique for examining patient samples for acid-fast bacilli. Cultured-Based Tests play an important role in laboratory confirmation and further characterization of suspected TB cases, although results generally require more time. Radiography Tests, particularly chest imaging, help healthcare professionals identify abnormalities that may be associated with pulmonary TB and are commonly used alongside laboratory-based diagnostics. The Others category includes additional and emerging diagnostic techniques that can support TB screening, detection, confirmation, and clinical assessment across different healthcare settings in the Asia Pacific region.

Request Customizationto receive a tailored report.

By End-User

Hospitals and Diagnostic Laboratories represent a major end-user segment due to their role in diagnosing and managing TB patients and their access to laboratory equipment and specialized testing facilities. Physician’s Office Laboratories support diagnostic assessment in outpatient settings, providing patients with greater convenience and enabling healthcare professionals to initiate appropriate testing. Reference Laboratories serve healthcare providers that require specialized or high-volume diagnostic services and can process samples using advanced testing capabilities. Academics and Research Facilities contribute to the development, evaluation, and validation of new TB diagnostic technologies, biomarkers, and testing methodologies. These institutions also support research focused on improving diagnostic accuracy, shortening testing time, and developing more accessible solutions for different healthcare environments.

Speak to an Analystto discuss market opportunities.

Regional Analysis

Asia-Pacific is the second-largest market for TB diagnostics, with an anticipated market value of USD 644 million by 2030, representing a CAGR of 5.7%. Through 2028, the Asia Pacific TB diagnostics market is expected to grow at a rapid pace. The rising number of breakthroughs in the field of TB testing is responsible for this rise. From laboratory-based molecular diagnostics to AI (artificial intelligence) for CXR (chest x-ray) interpretation, there are several devices on the market. In 2021, the World Health Organization recommended CAD (computer-aided detection) of CXRs based on the findings of investigations conducted by Lunit in South Korea and Qure.ai in India. The market is growing due to improvements in healthcare infrastructure in Asian nations, a high prevalence of this condition in a few countries, and rising desire among individuals for improved treatment outcomes. According to a study published in BMJ Global Health in November 2020, TB infected an estimated 2.64 million Indians in 2019 and killed almost 450,000 people in India.

List of Key and Emerging Players in Asia Pacific TB Diagnostics Market